@article{3078649,
    title = "A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)",
    author = "Dimopoulos, M.A. and Cavo, M. and Mateos, M.-V. and Facon, T. and Heeg, B. and van Beekhuizen, S. and Gebregergish, S.B. and Nair, S. and Pisini, M. and Lam, A. and Slavcev, M.",
    journal = "Clinical Lymphoma Myeloma and Leukemia",
    year = "2020",
    volume = "61",
    number = "3",
    pages = "714-720",
    publisher = "Taylor and Francis Ltd.",
    doi = "10.1080/10428194.2019.1682571",
    keywords = "antineoplastic agent;  bortezomib;  daratumumab;  dexamethasone;  immunoglobulin G;  lenalidomide;  melphalan;  prednisone;  thalidomide;  antineoplastic agent;  bortezomib;  daratumumab;  dexamethasone;  lenalidomide;  melphalan;  monoclonal antibody;  prednisone;  thalidomide, aged;  Article;  body surface;  cancer combination chemotherapy;  cancer patient;  cancer survival;  clinical outcome;  comparative study;  continuous infusion;  controlled study;  disease exacerbation;  female;  follow up;  human;  major clinical study;  male;  multiple cycle treatment;  multiple myeloma;  overall survival;  priority journal;  progression free survival;  randomized controlled trial;  treatment outcome, Antibodies, Monoclonal;  Antineoplastic Combined Chemotherapy Protocols;  Bortezomib;  Dexamethasone;  Humans;  Lenalidomide;  Melphalan;  Multiple Myeloma;  Prednisone;  Thalidomide;  Treatment Outcome",
    abstract = "D-VMP is a novel treatment for transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM). D-VMP significantly prolonged PFS versus VMP in the ALCYONE trial. The FIRST trial investigated Rd given in 28-day cycles until disease progression, Rd for 18 cycles, and MPT for 12 cycles for TIE NDMM. As no randomized controlled trials comparing D-VMP to standard-of-care regimens such as those in FIRST are available, an MAIC was performed to assess relative OS and PFS for D-VMP from ALYCONE and Rd continuous, Rd 18, and MPT from FIRST. Individual patient data for D-VMP in ALCYONE were weighted to match aggregated baseline patient characteristics for each arm of FIRST. D-VMP significantly improved OS versus MPT and Rd 18, with a trend favoring D-VMP versus Rd continuous. D-VMP performed significantly better than all FIRST comparators for PFS. This MAIC demonstrates OS and PFS benefits for D-VMP versus Rd continuous, Rd 18, and MPT. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group."
}